单位：[1]Mie Univ, Grad Sch Med, Dept Cardiol & Nephrol, Tsu, Mie 5148507, Japan[2]Fudan Univ, Zhongshan Hosp, Shanghai 200433, Peoples R China[3]Natl Clin Res Ctr Resp Dis, Beijing, Peoples R China[4]Capital Med Univ, Dept Resp Med, Beijing, Peoples R China[5]China Japan Friendship Hosp, Beijing, Peoples R China[6]CHA Univ, CHA Bundang Med Ctr, Gyeongghi Do, South Korea[7]Cheng Hsin Gen Hosp, Ctr Heart, Tokyo, Japan[8]Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan[9]Daiichi Sankyo Co Ltd, Clin Planning Dept, Tokyo, Japan[10]Daiichi Sankyo Co Ltd, Asia Dev Dept, Tokyo, Japan[11]Daiichi Sankyo Co Ltd, Clin Data & Biostat Dept, Tokyo, Japan[12]Daiichi Sankyo Pharma Dev, Clin Dev Dept, Edison, NJ USA[13]Singapore Gen Hosp, Dept Hematol, Singapore, Singapore[14]ITREAS, Brugg, Switzerland[15]Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
BackgroundDirect oral anticoagulants have been evaluated for their efficacy and safety in the treatment of venous thromboembolism (VTE), which comprises deep vein thrombosis and pulmonary embolism. The randomized, double-blind Hokusai-VTE trial demonstrated that 60mg of edoxaban once daily following initial heparin treatment is non-inferior to heparin overlapped with and followed by warfarin for the treatment of VTE, and is associated with significantly fewer bleeding events. ObjectivesTo assess the efficacy and safety of edoxaban versus warfarin among East Asian patients enrolled in the Hokusai-VTE trial. Patients/methodsThe Hokusai-VTE trial enrolled 8292 patients from 439 centers worldwide, including 1109 patients from Japan, China, Korea, and Taiwan. The primary efficacy and safety outcomes were symptomatic recurrent VTE and clinically relevant bleeding, respectively. ResultsIn the overall East Asian population, the primary efficacy outcome of symptomatic recurrent VTE occurred in 16 of 563 (2.8%) patients in the edoxaban group versus 24 of 538 (4.5%) patients in the warfarin group (hazard ratio [HR]0.64; 95% confidence interval [CI]0.34-1.19; P=0.1601). The primary safety outcome of clinically relevant bleeding occurred in 56 of 563 (9.9%) patients inthe edoxaban group versus 93 of 538 (17.3%) patients in the warfarin group (HR0.56; 95%CI0.40-0.78; P<0.001). ConclusionsEdoxaban is an effective and safer alternative to warfarin in East Asian patients with acute VTE who require anticoagulant therapy, consistent with overall study findings from the Hokusai-VTE trial.
第一作者单位：[1]Mie Univ, Grad Sch Med, Dept Cardiol & Nephrol, Tsu, Mie 5148507, Japan[*1]Mie Univ, Grad Sch Med, Dept Cardiol & Nephrol, 2-174 Edobashi, Tsu, Mie 5148507, Japan
通讯作者：
通讯机构：[1]Mie Univ, Grad Sch Med, Dept Cardiol & Nephrol, Tsu, Mie 5148507, Japan[*1]Mie Univ, Grad Sch Med, Dept Cardiol & Nephrol, 2-174 Edobashi, Tsu, Mie 5148507, Japan
推荐引用方式(GB/T 7714)：
Nakamura M.,Wang Y. Q.,Wang C.,et al.Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial[J].JOURNAL of THROMBOSIS and HAEMOSTASIS.2015,13(9):1606-1614.doi:10.1111/jth.13055.
APA：
Nakamura, M.,Wang, Y. Q.,Wang, C.,Oh, D.,Yin, W. -H....&Bueller, H..(2015).Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.JOURNAL of THROMBOSIS and HAEMOSTASIS,13,(9)
MLA：
Nakamura, M.,et al."Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial".JOURNAL of THROMBOSIS and HAEMOSTASIS 13..9(2015):1606-1614
医学